GlaxoSmithKline Pharmaceuticals Limited (GLAXO) AI Stock Analysis

GlaxoSmithKline Pharmaceuticals Limited

(NSE:GLAXO)

Select Model

Rating:77Outperform

Price Target:INR 2,729.00▲(9.88% Upside)

Action:upgraded

Date:08/17/26

The score is driven primarily by strong financial performance (improving profitability, minimal debt, and solid free cash flow quality) and supportive technical momentum (price above key moving averages with positive MACD). The main offset is valuation, with a high P/E that increases downside risk if growth or margins disappoint.

Positive Factors

Improving revenue and marginsThe return to steady revenue growth after 2023, combined with materially stronger 2026 margins, indicates improving operating performance. If maintained, this mix of top-line recovery and operating leverage can support more durable earnings growth and strengthen the company’s ability to reinvest in its branded portfolio.

Negative Factors

Interrupted revenue trajectoryThe 2023 revenue decline shows that the company’s top-line progression has not been uninterrupted. Although growth subsequently reaccelerated, the prior contraction raises the need for continued execution across its product portfolio and distribution channels to establish a consistently durable growth trajectory.

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 422.55B
Dividend Yield: 2.29%
Average Volume (3M): 10.90K
Price to Earnings (P/E): 39.6
Beta (1Y): 0.87
Revenue Growth: 5.75%
EPS Growth: 12.41%
Country: India
Employees: 3,103
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription a...

How the Company Makes Money

GLAXO makes money primarily by selling pharmaceutical and healthcare products through domestic and institutional channels. Its core revenue stream is product sales: (1) prescription medicines sold to hospitals, clinics, and pharmacies via wholesalers...

GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview

Summary

Strong fundamentals overall: improving margins through 2024–2026, very conservative leverage, and generally high-quality free cash flow generation. Key risks are profitability volatility (notably 2022 being non-recurring) and uneven operating cash flow conversion driven by variability in cash timing/working capital.

Income Statement

82Very Positive

Balance Sheet

92Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	39.55B	38.22B	37.26B	34.42B	32.26B	32.64B
Gross Profit	20.55B	16.65B	22.53B	20.22B	18.68B	18.14B
EBITDA	15.20B	14.75B	13.28B	8.88B	9.04B	8.49B
Net Income	10.68B	10.36B	9.28B	5.90B	6.11B	16.95B
Balance Sheet
Total Assets	0	43.24B	41.08B	35.57B	33.27B	46.33B
Cash, Cash Equivalents and Short-Term Investments	27.57B	27.56B	24.98B	18.57B	16.54B	29.03B
Total Debt	0	332.70M	99.50M	186.65M	155.40M	200.76M
Total Liabilities	-22.67B	20.56B	21.57B	17.79B	15.85B	19.70B
Stockholders Equity	22.67B	22.67B	19.51B	17.78B	17.41B	26.63B
Cash Flow
Free Cash Flow	1.67B	9.67B	12.67B	5.51B	4.40B	7.76B
Operating Cash Flow	1.84B	10.22B	12.90B	5.82B	4.84B	8.11B
Investing Cash Flow	3.40B	2.78B	-458.10M	87.12M	8.08B	-4.06B
Financing Cash Flow	-7.23B	-7.37B	-7.69B	-5.61B	-15.43B	-5.24B

GlaxoSmithKline Pharmaceuticals Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price2483.55

Price Trends

50DMA2766.10Negative

100DMA2614.26Negative

200DMA2485.41Negative

Market Momentum

MACD-77.92Negative

RSI37.88Neutral

STOCH67.12Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Negative. The current price of 2483.55 is below the 20-day moving average (MA) of 2544.66, below the 50-day MA of 2766.10, and below the 200-day MA of 2485.41, indicating a bearish trend. The MACD of -77.92 indicates Negative momentum. The RSI at 37.88 is Neutral, neither overbought nor oversold. The STOCH value of 67.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GLAXO.

GlaxoSmithKline Pharmaceuticals Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:GLAXO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ABBOTINDIA	81Outperform	INR 543.84B	33.74	―	2.05%	6.29%	11.18%
IN:CIPLA	79Outperform	INR 1.11T	38.44	―	2.10%	-0.74%	-46.77%
IN:GLAXO	77Outperform	INR 420.73B	39.56	―	2.29%	5.75%	12.41%
IN:PFIZER	67Neutral	INR 168.67B	22.95	―	2.03%	10.69%	-9.09%
IN:GLAND	65Neutral	INR 511.12B	45.19	―	0.65%	17.57%	46.53%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:GLAXO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:GLAXO	GlaxoSmithKline Pharmaceuticals Limited	2483.55	-135.33	-5.17%
IN:ABBOTINDIA	Abbott India Limited	25593.30	-2826.16	-9.94%
IN:CIPLA	Cipla Ltd	1380.00	-117.54	-7.85%
IN:GLAND	Gland Pharma Ltd.	3097.50	1140.16	58.25%
IN:PFIZER	PFIZER LIMITED	3687.05	-1407.11	-27.62%
IN:SANOFICONR	Sanofi Consumer Healthcare India Limited	3435.05	-1279.73	-27.14%

GlaxoSmithKline Pharmaceuticals Limited Corporate Events

GSK Pharma Shareholders Approve Board and Managing Director Appointments via Postal Ballot

Sep 15, 2026

GlaxoSmithKline Pharmaceuticals Limited is a Mumbai-based pharmaceutical company focused on developing, manufacturing, and marketing prescription medicines and vaccines for the Indian market. The company operates within the broader healthcare and lif...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 17, 2026

GlaxoSmithKline Pharmaceuticals Limited AI Stock Analysis